CAS: 6665-86-7; 7-Hydroxy-2-Phenyl-4H-Chromen-4-One

上下游产品

benzoylmethane4-(benzoyloxy)-2-hydroxybenzoylbenzoylmethane 3-benzoyl-4,7-dihydroxy-coumarin 7-(benzyloxy)-2-phenyl-4H-chromen-4-one 7-hydroxy-2-phenyl-3-benzoylchromone 7-Butoxycarbonylmethoxy-4-oxo-2-phenyl-4H-chromen 7-dichloroacetoxy-2-phenyl-chromen-4-one H-chromen-7-yloxy)-acetic acid isopropyl ester(4-oxo-2-phenyl-4H-chromen-7-yloxy)-acetic acid isopropyl ester H-chromen-7-yloxy)-acetic acid propyl ester(4-oxo-2-phenyl-4H-chromen-7-yloxy)-acetic acid propyl ester

丹皮酚置于碘,三溴化硼,Potassium Hydroxide体系中,用 甲醇,二氯甲烷,二甲基亚砜 作为反应溶剂,化学反应 16.0H,反应生成 7-羟基黄酮
参考文献:黄酮衍生物在电子激发态下的单分子和双分子内质子转移†
标题:黄酮衍生物在电子激发态下的单分子和双分子内质子转移†
摘要:为了创建能够参与激发态分子内双质子转移(esidpt)的黄酮衍生物,我们合成了3,7-二羟基黄酮的两个羰基衍生物,它们都包含两个不同的质子转移位点以及相关的3-羟基黄酮和7-羟基黄酮.发现所有检查的羟基黄酮均参与兴奋态分子内质子转移(esipt).与涉及7-羟基和6 / 8-羰基片段的esipt相比,涉及3-羟基和4-羰基的esipt具有更高的阻隔性.根据提供的数据,3,7-二羟基-2-苯基-6-(3-苯基丙酰基)-4 H-Chromen-4-One经历两阶段的esidpt,形成中间互变异构体.这种esidpt会导致互变异构形式,其激发态的辐射失活速率异常低,从而限制了低荧光量子产率.3,7-二羟基-4-氧代-2-苯基-4 H-亚甲基-8-甲醛在电子激发态下的行为类似于3-羟基黄酮衍生物,因此我们推断该化合物中存在单个esipt .
DOI:10.1039/c5Ra13912K

专利信息

专利号:US-12194020-B2
优先权日:2017-12-22
标 题:Reversing baldness through cannabinoid receptor activation
发明人：POSTREL RICHARD
权利人:POSTREL RICHARD
摘要:This invention reverses male pattern baldness by shocking dormant hair follicles out of their androgen induced hibernation phase back to the active hair-growing anagenic phase. The invention integrates two functions: 1) It blocks synthesis of compounds holding the follicles in the telogenic/hibernating phase and 2) It stimulates synthesis of compounds animating the hair-growing/anagenic phase in the follicular activity cycle. One preferred embodiment comprises an enzyme inhibitor blocking the conversion of testosterone to dihydrotestosterone (DHT), a flavonoid simultaneously increasing synthesis of prostaglandins alternative to prostaglandin D2, and a selected cannabinoid compound stimulating restore the hair follicle to its normal growth cycle. This novel trimodal therapy restores the hair follicles to their normal cycling processes and maintains these restorative properties so long as this rebalance in maintained.

专利号:WO-2025125811-A1
优先权日:2023-12-12
标题:Heterocyclic compounds and their use for the treatment of neurological disorders
发明人：PLOWRIGHT ALLEYN THOMAS; PFEIFFER THOMAS; MÄRCHER-RØRSTED EMIL; DUCKWORTH EDWARD JOSEPH
权利人:ONTRACK THERAPEUTICS LTD
摘要:The present invention relates to novel synthetic compounds of Formula (I) and (II) related to naturally occurring flavonoids such as 7,8-dihydroxyflavone (7,8-DHF). The invention further relates to the method of synthesis, the use of these compounds as research tools and their use as pharmaceuticals.

专利号:CN-105294627-A
优先权日:2015-11-04
标题:A method for one-step synthesis of flavonoids catalyzed by 1,3-dialkylimidazolium oxometalates

专利号:CN-105294627-B
优先权日:2015-11-04
标 题:A method for one-step synthesis of flavonoids catalyzed by 1,3-dialkylimidazolium oxometalates

专利号:US-8372380-B2
优先权日:2007-03-30
标 题:In vivo imaging of sulfotransferases
发明人：BARRIO JORGE R; KEPE VLADIMIR; SMALL GARY W; SATYAMURTHY NAGICHETTIAR
权利人:UNIV CALIFORNIA; BARRIO JORGE R; KEPE VLADIMIR; SMALL GARY W; SATYAMURTHY NAGICHETTIAR
摘要:Radiolabeled tracers for sulfotransferases (SULTs), their synthesis, and their use are provided. Included are substituted phenols, naphthols, coumarins, and flavones radiolabeled with 18 F, 123 I, 124 I, 125 I, or 11 C. Also provided are in vivo techniques for using these and other tracers as analytical and diagnostic tools to study sulfotransferase distribution and activity, in health and disease, and to evaluate therapeutic interventions.

专利号:US-2010280070-A1
优先权日:2008-01-04
标 题 :Novel tetrahydroquinolines as aromatase inhibitors
发明人：AKKINEPALLY RAGHURAM RAO
权利人:AKKINEPALLY RAGHURAM RAO
摘要:The invention relates to synthesis and biological screening of novel tetrahydroquinolines of formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them for aromatase inhibition: (I). The present invention also relates to a process for the preparation of the novel tetrahydroquinolines, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in for aromatase inhibition, particularly in the treatment and/or prevention of cancer, particularly breast cancer, more particularly hormone dependent breast cancer.